


Appl. No. 10/612,104  
 Atty. Docket No. 7490MC  
 Amdt. dated April 5, 2005  
 Reply to Office Action of March 14, 2005  
 Customer No. 27752


# AMENDMENTS TO THE CLAIMS

1. (Previously Presented) A cyclic peptide having the formula:




wherein B is a bridge moiety selected from:


i)



ii)




iii)




Appl. No. 10/612,104  
Atty. Docket No. 7490MC  
Amdt. dated April 5, 2005  
Reply to Office Action of March 14, 2005  
Customer No. 27752


iv)




v)




vi)



vii)




viii)




Appl. No. 10/612,104  
 Atty. Docket No. 7490MC  
 Amdt. dated April 5, 2005  
 Reply to Office Action of March 14, 2005  
 Customer No. 27752


ix)



2. (Previously Presented) A compound according to Claim 1 having the following stereochemical formula:




3. (Previously Presented) A cyclic peptide having the formula:




wherein B is a bridge moiety selected from:

i)


Appl. No. 10/612,104  
Atty. Docket No. 7490MC  
Amdt. dated April 5, 2005  
Reply to Office Action of March 14, 2005  
Customer No. 27752




ii)




iii)



iv)




v)




Appl. No. 10/612,104  
Atty. Docket No. 7490MC  
Amdt. dated April 5, 2005  
Reply to Office Action of March 14, 2005  
Customer No. 27752


vi)




vii)




viii)



ix)




x)




Appl. No. 10/612,104  
 Atty. Docket No. 7490MC  
 Amdt. dated April 5, 2005  
 Reply to Office Action of March 14, 2005  
 Customer No. 27752

4. (Previously Presented) A compound according to Claim 2 having the following stereochemical formula:




5. (Previously Presented) A composition comprising:  
 A) one or more cyclic peptides having the formula:




wherein B is a bridge moiety selected from:

i)




Appl. No. 10/612,104  
Atty. Docket No. 7490MC  
Amdt. dated April 5, 2005  
Reply to Office Action of March 14, 2005  
Customer No. 27752


ii)




iii)



iv)




v)




vi)


Appl. No. 10/612,104  
 Atty. Docket No. 7490MC  
 Amdt. dated April 5, 2005  
 Reply to Office Action of March 14, 2005  
 Customer No. 27752




vii)



viii)



ix)




B) one or more excipients.

6. (Previously Presented) A composition according to Claim 5 wherein said cyclic peptides have the following stereochemical formula:




Appl. No. 10/612,104  
 Atty. Docket No. 7490MC  
 Amdt. dated April 5, 2005  
 Reply to Office Action of March 14, 2005  
 Customer No. 27752




7. (Previously Presented) A composition comprising:

A) one or more cyclic peptides having the formula:




wherein B is a bridge moiety selected from:

i)




ii)


Appl. No. 10/612,104  
Atty. Docket No. 7490MC  
Amdt. dated April 5, 2005  
Reply to Office Action of March 14, 2005  
Customer No. 27752




iii)




iv)



v)




vi)




Appl. No. 10/612,104  
 Atty. Docket No. 7490MC  
 Amdt. dated April 5, 2005  
 Reply to Office Action of March 14, 2005  
 Customer No. 27752


vii)




viii)



ix)




x)



B) one or more excipients.


8. (Previously Presented) A composition according to Claim 7 wherein said cyclic peptides have the following stereochemical formula:

Appl. No. 10/612,104  
 Atty. Docket No. 7490MC  
 Amdt. dated April 5, 2005  
 Reply to Office Action of March 14, 2005  
 Customer No. 27752




9. (Currently Amended) A method of stimulating the melanocortin-4 (MC-4) receptor in a mammal comprising administering to a mammal in need thereof a composition comprising a cyclic peptide, for a time and under conditions effective to stimulate the MC-4 ~~MC-4~~ receptor, said composition comprising:

A) one or more cyclic peptides having the formula:




wherein B is a bridge moiety selected from:

i)




Appl. No. 10/612,104  
Atty. Docket No. 7490MC  
Amdt. dated April 5, 2005  
Reply to Office Action of March 14, 2005  
Customer No. 27752


ii)




iii)



iv)




v)




vi)


Appl. No. 10/612,104  
 Atty. Docket No. 7490MC  
 Amdt. dated April 5, 2005  
 Reply to Office Action of March 14, 2005  
 Customer No. 27752




vii)



viii)



ix)




B) one or more excipients.

10. (Previously presented) A method for suppressing appetite in a human who is endeavoring to reduce caloric intake comprising administering to said human a composition comprising a cyclic peptide, for a time and under conditions effective to stimulate the melanocortin-4 receptor, said composition comprising:


A) one or more cyclic peptides having the formula:

Appl. No. 10/612,104  
 Atty. Docket No. 7490MC  
 Amdt. dated April 5, 2005  
 Reply to Office Action of March 14, 2005  
 Customer No. 27752




wherein B is a bridge moiety selected from:


i)



ii)




iii)




iv)


Appl. No. 10/612,104  
Atty. Docket No. 7490MC  
Amdt. dated April 5, 2005  
Reply to Office Action of March 14, 2005  
Customer No. 27752




v)




vi)



vii)




viii)






Appl. No. 10/612,104  
Atty. Docket No. 7490MC  
Amdt. dated April 5, 2005  
Reply to Office Action of March 14, 2005  
Customer No. 27752

ix)



x)



B) one or more excipients.